Ankylosing spondylitis

Global Ankylosing Spondylitis Market Outlook Report 2020: Market Accounted for $4.38 Billion in 2019 and is Expected to Reach $9.59 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 29, 2020
General Health, Surgery, Health, Genetics, Pharmaceutical, Medical specialties, Clinical medicine, Rheumatology, Ankylosing spondylitis, Arthritis, Spondylitis

The "Ankylosing Spondylitis - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ankylosing Spondylitis - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.
  • Global Ankylosing Spondylitis market accounted for $4.38 billion in 2019 and is expected to reach $9.59 billion by 2027 growing at a CAGR of 10.3% during the forecast period.
  • Rising prevalence of Ankylosing Spondylitis is growing awareness about diagnostics and treatments for the disease.
  • Additionally, government initiatives and getting better healthcare infrastructure are the major factors propelling the market growth.

Global Ankylosing Spondylitis Market Outlook to 2027 by Molecule Type, RoA, Dosage Form, Drug, Drug Type, Treatment, Application, End-user, Competitive Landscape

Retrieved on: 
Friday, November 13, 2020
Medical specialties, Clinical medicine, Rheumatology, Spondylitis, Ankylosing spondylitis, Monoclonal antibodies

DUBLIN, Nov. 13, 2020 /PRNewswire/ -- The "Ankylosing Spondylitis - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 13, 2020 /PRNewswire/ -- The "Ankylosing Spondylitis - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.
  • Global Ankylosing Spondylitis Market accounted for $4.38 billion in 2019 and is expected to reach $9.59 billion by 2027, growing at a CAGR of 10.3% during the forecast period.
  • Rising prevalence of Ankylosing Spondylitis, growing awareness about diagnostics and treatments for the disease.
  • Covers Market data for the years 2018, 2019, 2020, 2024, and 2027
    Company profiling with detailed strategies, financials, and recent developments

Survey Reveals Rheumatologists Can Positively Impact Treatment Journey for People with Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis

Retrieved on: 
Monday, November 9, 2020
Medical specialties, Arthritis, Clinical medicine, Organ systems, Axial spondyloarthritis, Autoimmune diseases, Rheumatology, Musculoskeletal disorders, Ankylosing spondylitis, Spondyloarthropathy, Spondylitis

The Ankylosing Spondylitis/Axial Spondyloarthritis In America survey illuminates the perspectives and experiences of people living with both ankylosing spondylitis and non-radiographic axial spondyloarthritis.

Key Points: 
  • The Ankylosing Spondylitis/Axial Spondyloarthritis In America survey illuminates the perspectives and experiences of people living with both ankylosing spondylitis and non-radiographic axial spondyloarthritis.
  • AxSpA commonly refers to non-radiographic axial spondyloarthritis (nr-AxSpA), wherein no characteristic damage of the sacroiliac joints or spinal fusing appears on x-rays.
  • On the other hand, when people have radiographic axial spondyloarthritis, which is commonly referred to as ankylosing spondylitis (AS), characteristic damage is evident on x-rays.
  • The Ankylosing Spondylitis/Axial Spondyloarthritis In America survey was fielded from March 23 to July 22, 2020.

Global Ankylosing Spondylitis Market Outlook Report 2020: Market Accounted for $4.38 Billion in 2019 and is Expected to Reach $9.59 billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 9, 2020
Health, Other Health, Medical specialties, Clinical medicine, Rheumatology, Spondylitis, Ankylosing spondylitis

The "Ankylosing Spondylitis - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ankylosing Spondylitis - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.
  • Global Ankylosing Spondylitis Market accounted for $4.38 billion in 2019 and is expected to reach $9.59 billion by 2027, growing at a CAGR of 10.3% during the forecast period.
  • Rising prevalence of Ankylosing Spondylitis, growing awareness about diagnostics and treatments for the disease.
  • Covers Market data for the years 2018, 2019, 2020, 2024, and 2027
    Company profiling with detailed strategies, financials, and recent developments

Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS)

Retrieved on: 
Friday, November 6, 2020
Medical devices, FDA, Fitness & Nutrition, Clinical trials, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, Medical specialties, Clinical medicine, Immunosuppressants, Medicine, Tofacitinib, Ankylosing spondylitis, Pfizer, Spondylitis, the AS Study, Ankylosing Spondylitis (AS), XELJANZ® (tofacitinib), Pfizer Inflammation & Immunology

Pfizer Inc. (NYSE: PFE) announced today positive results from a Phase 3 investigational study evaluating the safety and efficacy of tofacitinib in adults with active ankylosing spondylitis (AS).

Key Points: 
  • Pfizer Inc. (NYSE: PFE) announced today positive results from a Phase 3 investigational study evaluating the safety and efficacy of tofacitinib in adults with active ankylosing spondylitis (AS).
  • The AS study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study that included 270 adult patients with active AS.
  • * Unless otherwise stated, XELJANZ in the Important Safety Information refers to XELJANZ, XELJANZ XR, and XELJANZ Oral Solution.
  • Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study.

Musculoskeletal Disorders Pipeline Database 2020: Osteoarthritis, Osteoporosis, Rheumatoid Arthritis, Systemic lupus erythematosus, and Ankylosing Spondylitis - ResearchAndMarkets.com

Retrieved on: 
Friday, September 18, 2020
Health, General Health, Medical specialties, Clinical medicine, Medicine, RTT, Rheumatology, Arthritis, Autoimmune diseases, Skeletal disorders, Rheumatism, Rheumatoid arthritis, Ankylosing spondylitis, Osteoarthritis

Musculoskeletal Disorders Pipeline Highlights Database - 2020, provides the most up-to-date information on key pipeline products in the global Musculoskeletal Disorders market.

Key Points: 
  • Musculoskeletal Disorders Pipeline Highlights Database - 2020, provides the most up-to-date information on key pipeline products in the global Musculoskeletal Disorders market.
  • It covers emerging therapies for Musculoskeletal Disorders in active clinical development stages including early and late stage clinical trials.
  • Key indications covered in this database include Osteoarthritis, Osteoporosis, Rheumatoid Arthritis, Systemic lupus erythematosus, and Ankylosing Spondylitis.
  • Key indications covered in this database include Osteoarthritis, Osteoporosis, Rheumatoid Arthritis, Systemic lupus erythematosus, and Ankylosing Spondylitis.

United States Ankylosing Spondylitis Market 2016-2025: Pipeline, Epidemiology, Key Products, Market Valuations & Forecast, Drugs Sales and Market Shares - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 3, 2020
Health, Pharmaceutical, Medical specialties, Clinical medicine, Drugs, Rheumatology, RTT, Ankylosing spondylitis, Arthritis, Spondylitis, Monoclonal antibodies, Axial spondyloarthritis

The report provides comprehensive insights into Ankylosing Spondylitis pipeline products, Ankylosing Spondylitis epidemiology, Ankylosing Spondylitis market valuations and forecast, Ankylosing Spondylitis drugs sales and competitive landscape in the US.

Key Points: 
  • The report provides comprehensive insights into Ankylosing Spondylitis pipeline products, Ankylosing Spondylitis epidemiology, Ankylosing Spondylitis market valuations and forecast, Ankylosing Spondylitis drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Ankylosing Spondylitis treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Ankylosing Spondylitis pipeline: Find out the products in clinical trials for the treatment of Ankylosing Spondylitis by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Ankylosing Spondylitis drugs: Identify key products marketed and prescribed for Ankylosing Spondylitis in the US, including trade name, molecule name, and company
    Ankylosing Spondylitis market valuations: Find out the market size for Ankylosing Spondylitis drugs in 2019 in the US.
  • Find out how the market advanced from 2016 and forecast to 2025
    Ankylosing Spondylitis drugs market share: Find out the market shares for key Ankylosing Spondylitis drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Ankylosing Spondylitis products

AbbVie Submits Regulatory Application to FDA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis

Retrieved on: 
Tuesday, August 25, 2020
Health, Medical specialties, Clinical research, Design of experiments, Pyrrolidines, Organofluorides, Upadacitinib, Ureas, Ankylosing spondylitis, Placebo-controlled study, Clinical trial, Tofacitinib

You should not breastfeed while taking RINVOQ and for at least 6 days after your last dose.

Key Points: 
  • You should not breastfeed while taking RINVOQ and for at least 6 days after your last dose.
  • RINVOQ can make you more likely to get infections or make any infections you have worse.
  • Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients With Active Ankylosing Spondylitis.
  • A Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis (SELECT Axis 1).

Ankylosing Spondylitis Treatment Market to Witness Impressive Growth on the back of Increased Research: Future Market Insights

Retrieved on: 
Wednesday, August 19, 2020
Medical specialties, Clinical medicine, Medicine, TNF inhibitors, Immunosuppressants, RTT, Monoclonal antibodies, Rheumatology, Ankylosing spondylitis, Infliximab, Spondylitis

DUBAI, U.A.E, Aug. 19, 2020 /PRNewswire/ -- A new market study by Future Market Insights (FMI) forecasted that the ankylosing spondylitis treatment market will expand at a healthy rate between 2020 and 2030.

Key Points: 
  • DUBAI, U.A.E, Aug. 19, 2020 /PRNewswire/ -- A new market study by Future Market Insights (FMI) forecasted that the ankylosing spondylitis treatment market will expand at a healthy rate between 2020 and 2030.
  • The growth of the market is majorly attributed to the rising incidence of spondylitis among people across the world.
  • Increased spending in the healthcare industry on extensive research pertaining to ankylosing spondylitis is encouraging market players to innovate novel treatment methods.
  • In Dec 2019, Avsola (infliximab-axxq) by Amgen obtained approval from the US FDA to be used in the treatment of ankylosing spondylitis.

Ankylosing Spondylitis Treatment Market to Witness Impressive Growth on the back of Increased Research: Future Market Insights

Retrieved on: 
Wednesday, August 19, 2020
Medical specialties, Clinical medicine, Medicine, TNF inhibitors, Immunosuppressants, RTT, Monoclonal antibodies, Rheumatology, Ankylosing spondylitis, Infliximab, Spondylitis

DUBAI, U.A.E, Aug. 19, 2020 /PRNewswire/ -- A new market study by Future Market Insights (FMI) forecasted that the ankylosing spondylitis treatment market will expand at a healthy rate between 2020 and 2030.

Key Points: 
  • DUBAI, U.A.E, Aug. 19, 2020 /PRNewswire/ -- A new market study by Future Market Insights (FMI) forecasted that the ankylosing spondylitis treatment market will expand at a healthy rate between 2020 and 2030.
  • The growth of the market is majorly attributed to the rising incidence of spondylitis among people across the world.
  • Increased spending in the healthcare industry on extensive research pertaining to ankylosing spondylitis is encouraging market players to innovate novel treatment methods.
  • In Dec 2019, Avsola (infliximab-axxq) by Amgen obtained approval from the US FDA to be used in the treatment of ankylosing spondylitis.